Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial
Abstract Aim This study aimed to investigate whether sesame oil (SO) consumption could improve biomarkers of glycemic control, inflammation, and oxidative stress in women with metabolic dysfunction-associated steatotic liver disease (MASLD). Methods This randomized, double-blind, controlled trial in...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Nutrition |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40795-025-01123-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238837765603328 |
|---|---|
| author | Masoumeh Atefi Hamid Vahedi Mina Darand Mohammad Hassan Entezari |
| author_facet | Masoumeh Atefi Hamid Vahedi Mina Darand Mohammad Hassan Entezari |
| author_sort | Masoumeh Atefi |
| collection | DOAJ |
| description | Abstract Aim This study aimed to investigate whether sesame oil (SO) consumption could improve biomarkers of glycemic control, inflammation, and oxidative stress in women with metabolic dysfunction-associated steatotic liver disease (MASLD). Methods This randomized, double-blind, controlled trial included 60 women with MASLD (aged 20–50 years, body mass index (BMI) 25–40 kg/m²) assigned to either SO or sunflower oil (SFO) group (n = 30 each), who consumed 30 g/day for 12 weeks alongside a 500 kcal/day calorie-restricted diet. Serum fasting blood glucose (FBG), fasting serum insulin (FSI), homeostatic model assessment for insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), quantitative insulin sensitivity check index (QUICKI), serum high-sensitivity C-reactive protein (hs-CRP), and serum malondialdehyde (MDA) were measured at the pre- and post-intervention phases. Results Compared with the control, SO supplementation led to significant improvements in FBG (mean difference: -18.2 mg/dL; 95% confidence interval (CI): -25.0 to -11.4; Cohen’s d = 0.84), FSI (-3.2 µIU/mL; 95% CI: -4.5 to -1.9; d = 0.76), HOMA-IR (-1.4; 95% CI: -2.0 to -0.8; d = 0.81), HOMA-β (+ 15.6; 95% CI: +7.4 to + 23.8; d = 0.67), and QUICKI (+ 0.07; 95% CI: +0.03 to + 0.11; d = 0.72) (p < 0.05 for all). The reductions in hs-CRP (-0.05 mg/dL; 95% CI: -0.15 to + 0.05; d = 0.12) and MDA (-0.6 µmol/L; 95% CI: -1.4 to + 0.2; d = 0.28) were not significant (p > 0.05). Both groups presented significant weight loss, with no significant difference between them (p > 0.05). Conclusions SO consumption significantly improved glycemic control biomarkers in women with MASLD, suggesting potential metabolic benefits beyond weight loss. Trial registration This study was approved by the Institutional Review Board of Isfahan University of Medical Sciences (code: IR.MUI.RESEARCH.REC.1399.548), and it is registered at https://www.irct.ir/trial/52288 , IRCT20140208016529N6, Registration Date: 2020-12-12). |
| format | Article |
| id | doaj-art-3d6711b027c84da797b1ddceea0063c6 |
| institution | Kabale University |
| issn | 2055-0928 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nutrition |
| spelling | doaj-art-3d6711b027c84da797b1ddceea0063c62025-08-20T04:01:24ZengBMCBMC Nutrition2055-09282025-07-0111111510.1186/s40795-025-01123-0Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trialMasoumeh Atefi0Hamid Vahedi1Mina Darand2Mohammad Hassan Entezari3Environmental and Occupational Health Research Center, Shahroud University of Medical SciencesDepartment of Gastroenterology, School of Medicine, Shahroud University of Medical SciencesPrevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical SciencesFood Security Research Center, Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of Medical SciencesAbstract Aim This study aimed to investigate whether sesame oil (SO) consumption could improve biomarkers of glycemic control, inflammation, and oxidative stress in women with metabolic dysfunction-associated steatotic liver disease (MASLD). Methods This randomized, double-blind, controlled trial included 60 women with MASLD (aged 20–50 years, body mass index (BMI) 25–40 kg/m²) assigned to either SO or sunflower oil (SFO) group (n = 30 each), who consumed 30 g/day for 12 weeks alongside a 500 kcal/day calorie-restricted diet. Serum fasting blood glucose (FBG), fasting serum insulin (FSI), homeostatic model assessment for insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), quantitative insulin sensitivity check index (QUICKI), serum high-sensitivity C-reactive protein (hs-CRP), and serum malondialdehyde (MDA) were measured at the pre- and post-intervention phases. Results Compared with the control, SO supplementation led to significant improvements in FBG (mean difference: -18.2 mg/dL; 95% confidence interval (CI): -25.0 to -11.4; Cohen’s d = 0.84), FSI (-3.2 µIU/mL; 95% CI: -4.5 to -1.9; d = 0.76), HOMA-IR (-1.4; 95% CI: -2.0 to -0.8; d = 0.81), HOMA-β (+ 15.6; 95% CI: +7.4 to + 23.8; d = 0.67), and QUICKI (+ 0.07; 95% CI: +0.03 to + 0.11; d = 0.72) (p < 0.05 for all). The reductions in hs-CRP (-0.05 mg/dL; 95% CI: -0.15 to + 0.05; d = 0.12) and MDA (-0.6 µmol/L; 95% CI: -1.4 to + 0.2; d = 0.28) were not significant (p > 0.05). Both groups presented significant weight loss, with no significant difference between them (p > 0.05). Conclusions SO consumption significantly improved glycemic control biomarkers in women with MASLD, suggesting potential metabolic benefits beyond weight loss. Trial registration This study was approved by the Institutional Review Board of Isfahan University of Medical Sciences (code: IR.MUI.RESEARCH.REC.1399.548), and it is registered at https://www.irct.ir/trial/52288 , IRCT20140208016529N6, Registration Date: 2020-12-12).https://doi.org/10.1186/s40795-025-01123-0Glycemic controlInflammationOxidative stressMetabolic dysfunction-associated steatotic liver diseaseSesame oil |
| spellingShingle | Masoumeh Atefi Hamid Vahedi Mina Darand Mohammad Hassan Entezari Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial BMC Nutrition Glycemic control Inflammation Oxidative stress Metabolic dysfunction-associated steatotic liver disease Sesame oil |
| title | Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial |
| title_full | Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial |
| title_fullStr | Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial |
| title_full_unstemmed | Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial |
| title_short | Sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, controlled clinical trial |
| title_sort | sesame oil improves biomarkers of glycemic control in women with metabolic dysfunction associated steatotic liver disease a randomized double blind controlled clinical trial |
| topic | Glycemic control Inflammation Oxidative stress Metabolic dysfunction-associated steatotic liver disease Sesame oil |
| url | https://doi.org/10.1186/s40795-025-01123-0 |
| work_keys_str_mv | AT masoumehatefi sesameoilimprovesbiomarkersofglycemiccontrolinwomenwithmetabolicdysfunctionassociatedsteatoticliverdiseasearandomizeddoubleblindcontrolledclinicaltrial AT hamidvahedi sesameoilimprovesbiomarkersofglycemiccontrolinwomenwithmetabolicdysfunctionassociatedsteatoticliverdiseasearandomizeddoubleblindcontrolledclinicaltrial AT minadarand sesameoilimprovesbiomarkersofglycemiccontrolinwomenwithmetabolicdysfunctionassociatedsteatoticliverdiseasearandomizeddoubleblindcontrolledclinicaltrial AT mohammadhassanentezari sesameoilimprovesbiomarkersofglycemiccontrolinwomenwithmetabolicdysfunctionassociatedsteatoticliverdiseasearandomizeddoubleblindcontrolledclinicaltrial |